AI is a worry for many workers and ‘front of mind’ for employers, Manpower says
[ad_1] In headhunter Manpower’s post-earnings call with analysts, CEO Jonas Prising addressed what everyone was thinking, how artificial intelligence was affecting the job market. [ad_2]
Political unrest got you rattled? Experts share what to do with your money.
[ad_1] Financial experts offer money tips for people trying to navigate feelings about the uncertain future. “What we can control is what we’re doing with
Who might be the Democratic vice-presidential nominee if Biden steps aside? Here’s what betting markets say.
[ad_1] With pressure growing on President Joe Biden to step aside as the Democratic nominee, who might a new nominee’s running mate be? [ad_2] Source
Why PayPal’s ‘perplexing’ stock just got downgraded, while Block’s got upgraded
[ad_1] A William Blair analyst thinks PayPal faces “intractable competitive challenges” from Apple. [ad_2] Source link
Why Nvidia, AMD shares are rebounding after chip sector’s worst drop since 2020
[ad_1] Prominent chip stocks are bouncing back Thursday in the wake of upbeat, AI-fueled results from TSMC. [ad_2] Source link
Jobless claims jump t0 243,000 and match nearly one-year high
[ad_1] The number of Americans who applied for unemployment benefits last week shot up to 243,000 and matched a nearly one-year high, driven by a
Trump and Vance want a weaker U.S. dollar. Be careful what you wish for.
[ad_1] By picking J.D. Vance as his running mate, former President Donald Trump has sent an unmistakable signal that, should he return to the White
A Trump-Vance victory should be bearish for the dollar and Treasurys
[ad_1] A Donald Trump victory in the race for the White House, and a Republican sweep of both houses of Congress, should logically be bearish
Hedge funds that try to avoid pain just saw their worst day in nearly two years
[ad_1] Managers with long/short strategies — i.e., funds that combine bets that companies will appreciate in value with bets that others will decline — had
Novartis lifts guidance again as demand climbs for top drugs
[ad_1] Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to